Opportunities and Challenges in the Cancer biomarker Market
The Cancer biomarker Market offers immense opportunities, from early cancer detection to targeted therapies. Biopharma companies are leveraging biomarkers to enhance clinical trial efficiency and drug approvals.
However, challenges remain, including high testing costs, limited biomarker validation, and regulatory hurdles. Overcoming these barriers will be key to unlocking the market’s full potential in global healthcare.
Market Outlook: With a market size of USD 15.9 billion in 2022, the sector is expected to grow to USD 27.8 billion by 2030, at a healthy 9.8% CAGR.